Sfoglia per Autore
Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction
2011 S. Santaguida, C. Vernieri, F. Villa, A. Ciliberto, A. Musacchio, F. RI villa
Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55
2013 C. Vernieri, E. Chiroli, V. Francia, F. Gross, A. Ciliberto
THE INTERPLAY BETWEEN CDK1/CLBS AND PP2A/CDC55 IN ADAPTATION TO THE SPINDLE ASSEMBLY CHECKPOINT (SAC)
2014 C. Vernieri
The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes
2014 C.L. Crespo, C. Vernieri, P.J. Keller, M. Garrè, J.R. Bender, J. Wittbrodt, R. Pardi
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
2016 S. Pusceddu, F. De Braud, G. Lo Russo, L. Concas, D. Femia, C. Vernieri, A. Indini, B. Formisano, R. Buzzoni
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes
2016 S. Pusceddu, R. Buzzoni, C. Vernieri, L. Concas, S. Marceglia, L. Giacomelli, M. Milione, L. Leuzzi, D. Femia, B. Formisano, V. Mazzaferro, F. De Braud
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
2016 C. Vernieri, D. Femia, S. Pusceddu, C. Capella, J. Rosai, G. Calareso, L. Concas, N. Prinzi, G. Lo Russo, F. De Braud, R. Buzzoni
Update on medical treatment of small intestinal neuroendocrine tumors
2016 S. Pusceddu, D. Femia, G. Lo Russo, S. Ortolani, M. Milione, M. Maccauro, C. Vernieri, N. Prinzi, L. Concas, L. Leuzzi, F. De Braud, R. Buzzoni
Targeting cancer metabolism : Dietary and pharmacologic interventions
2016 C. Vernieri, S. Casola, M. Foiani, F. Pietrantonio, F. de Braud, V. Longo
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential
2017 S. Pusceddu, E. Verzoni, N. Prinzi, A. Mennitto, D. Femia, P. Grassi, L. Concas, C. Vernieri, G. Lo Russo, G. Procopio
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
2017 F. Pietrantonio, C. Vernieri, G. Siravegna, A. Mennitto, R. Berenato, F. Perrone, A. Gloghini, E. Tamborini, S. Lonardi, F. Morano, B. Picciani, A. Busico, C.C. Volpi, A. Martinetti, F. Battaglin, I. Bossi, A. Pellegrinelli, M. Milione, C. Cremolini, M. Di Bartolomeo, A. Bardelli, F. De Braud
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
2017 D. Oddo, G. Siravegna, A. Gloghini, C. Vernieri, B. Mussolin, F. Morano, G. Crisafulli, R. Berenato, G. Corti, C.C. Volpi, M. Buscarino, M. Niger, P.D. Dunne, G. Rospo, E. Valtorta, A. Bartolini, G. Fucà, S. Lamba, A. Martinetti, M. Di Bartolomeo, F. De Braud, A. Bardelli, F. Pietrantonio, F. Di Nicolantonio
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors
2017 S. Pusceddu, N. Prinzi, G. Lo Russo, D. Femia, M. Milione, F. Perrone, E. Tamborini, L. Concas, I. Pulice, C. Vernieri, F. Corti, R. Buzzoni, F. De Braud
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
2017 C. Vernieri, M. Milano, A. Mennitto, C. Maggi, B. Ferrari, L. Rinaldi, R. Mennitto, C. Stefanetti, B. Re, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
2018 S. Pusceddu, C. Vernieri, M. Di Maio, R. Marconcin, F. Spada, S. Massironi, T. Ibrahim, M. Brizzi, D. Campana, A. Faggiano, D. Giuffrida, M. Rinzivillo, S. Cingarlini, F. Aroldi, L. Antonuzzo, R. Berardi, L. Catena, C. De Divitiis, P. Ermacora, V. Perfetti, A. Fontana, P. Razzore, C. Carnaghi, V. Maria, C. Cauchi, M. Duro, S. Sergio, N. Fazio, F. Cavalcoli, A. Bongiovanni, A. La Salvia, N. Brighi, A. Colao, I. Puliafito, F. Panzuto, S. Ortolani, A. Zaniboni, F. Di Costanzo, M. Torniai, E. Bajetta, S. Tafuto, S. Garattini, D. Femia, N. Prinzi, L. Concas, G. Lo Russo, M. Milione, L. Giacomelli, R. Buzzoni, G. Delle Fave, V. Mazzaferro, F. de Braud
Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process
2018 P. Bonaiuti, E. Chiroli, F. Gross, A. Corno, C. Vernieri, M. Štefl, M. Cosentino Lagomarsino, M. Knop, A. Ciliberto
Diet and supplements in cancer prevention and treatment : clinical evidences and future perspectives
2018 C. Vernieri, F. Nichetti, A. Raimondi, S. Pusceddu, M. Platania, F. Berrino, F. de Braud
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer
2018 C. Vernieri, A. Mennitto, M. Prisciandaro, V. Huber, M. Milano, L. Rinaldi, M. Cona, C. Maggi, B. Ferrari, S. Manoukian, G. Mariani, G. Bianchi, G. Capri, L. Rivoltini, F. de Braud
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
2018 G. Procopio, M. Prisciandaro, R. Iacovelli, E. Cortesi, G. Fornarini, G. Facchini, G. Cartenì, R. Sabbatini, G. Del Bene, L. Galli, C. Caserta, A.G. Multari, M. Bregni, F. Massari, S. Buti, U. De Giorgi, F. Zustovich, M. Milella, F. Calabrò, M.L. Mancini, G. Tortora, C. Vernieri, D. Santini, M. Sorarù, R. Ricotta, C. Masini, M. Tucci, S.L. Fedeli, C. Ortega, A. Mecozzi, R. Ratta, C.N. Sternberg, E. Verzoni
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
2018 M. Moro, E. Caiola, M. Ganzinelli, E. Zulato, E. Rulli, M. Marabese, G. Centonze, A. Busico, U. Pastorino, F. de Braud, C. Vernieri, M. Simbolo, E. Bria, A. Scarpa, S. Indraccolo, M. Broggini, G. Sozzi, M. Garassino
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile